RU1826977C - Способ получени твердой дисперсной композиции - Google Patents

Способ получени твердой дисперсной композиции

Info

Publication number
RU1826977C
RU1826977C SU4202275A SU4202275A RU1826977C RU 1826977 C RU1826977 C RU 1826977C SU 4202275 A SU4202275 A SU 4202275A SU 4202275 A SU4202275 A SU 4202275A RU 1826977 C RU1826977 C RU 1826977C
Authority
RU
Russia
Prior art keywords
compound
solution
organic solvent
added
lactose
Prior art date
Application number
SU4202275A
Other languages
English (en)
Russian (ru)
Inventor
Уеда Есио
Симое Фумио
Симазаки Ясуо
Кадо Казутаке
Хонбо Тосиясу
Original Assignee
Фудзисава Фармасьютикал Ко., Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фудзисава Фармасьютикал Ко., Лтд filed Critical Фудзисава Фармасьютикал Ко., Лтд
Application granted granted Critical
Publication of RU1826977C publication Critical patent/RU1826977C/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Reinforced Plastic Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Colloid Chemistry (AREA)
SU4202275A 1986-04-02 1987-04-01 Способ получени твердой дисперсной композиции RU1826977C (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868608080A GB8608080D0 (en) 1986-04-02 1986-04-02 Solid dispersion composition

Publications (1)

Publication Number Publication Date
RU1826977C true RU1826977C (ru) 1993-07-07

Family

ID=10595572

Family Applications (1)

Application Number Title Priority Date Filing Date
SU4202275A RU1826977C (ru) 1986-04-02 1987-04-01 Способ получени твердой дисперсной композиции

Country Status (16)

Country Link
US (1) US4916138A (cg-RX-API-DMAC7.html)
EP (1) EP0240773B1 (cg-RX-API-DMAC7.html)
JP (1) JPS62277321A (cg-RX-API-DMAC7.html)
KR (2) KR950007209B1 (cg-RX-API-DMAC7.html)
AT (1) ATE73327T1 (cg-RX-API-DMAC7.html)
CA (1) CA1302279C (cg-RX-API-DMAC7.html)
DE (1) DE3777223D1 (cg-RX-API-DMAC7.html)
DK (1) DK174979B1 (cg-RX-API-DMAC7.html)
ES (1) ES2032397T3 (cg-RX-API-DMAC7.html)
GB (1) GB8608080D0 (cg-RX-API-DMAC7.html)
GR (1) GR3004124T3 (cg-RX-API-DMAC7.html)
HK (1) HK6397A (cg-RX-API-DMAC7.html)
IE (1) IE59712B1 (cg-RX-API-DMAC7.html)
MX (1) MX9202945A (cg-RX-API-DMAC7.html)
RU (1) RU1826977C (cg-RX-API-DMAC7.html)
UA (1) UA13209A (cg-RX-API-DMAC7.html)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366971A (en) * 1987-11-09 1994-11-22 Sandoz Ltd. Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them
ATE84213T1 (de) * 1987-11-11 1993-01-15 Pharmascience Lab Exifon und ein wasserloesliches polymer enthaltende pharmazeutische zubereitung.
JPH02206A (ja) * 1987-11-11 1990-01-05 Fujisawa Pharmaceut Co Ltd エキシホンと水溶性高分子化合物とを含有することを特徴とする新規製剤
FR2640137A1 (fr) * 1988-12-08 1990-06-15 Texinfine Sa Systemes transporteurs de principes actifs lipophiles et leur procede d'obtention
DK0406791T3 (da) * 1989-07-05 1995-03-27 Fujisawa Pharmaceutical Co Vandigt flydende præparat til ekstern anvendelse
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
EP0489181B1 (en) * 1990-07-19 1996-10-02 Otsuka Pharmaceutical Co., Ltd. Solid preparation
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5250678A (en) 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
WO1994010981A1 (fr) * 1992-11-18 1994-05-26 Fujisawa Pharmaceutical Co., Ltd. Preparation pharmaceutique a action prolongee
DE4316537A1 (de) * 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
CN1137680C (zh) 1995-09-19 2004-02-11 藤泽药品工业株式会社 气雾剂组合物
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
CN1259053A (zh) 1997-04-11 2000-07-05 藤泽药品工业株式会社 药物组合物
PT1421939E (pt) * 1998-03-26 2010-07-12 Astellas Pharma Inc Preparaã†o da libertaã†o sustentada de um composto de macrëlido como tracolimus
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
AU782447C (en) * 1999-04-30 2006-07-13 Regents Of The University Of Michigan, The Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US7572788B2 (en) 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
CA2399198A1 (en) 2000-02-18 2001-08-23 Christopher Carreras Motilide compounds
US6750047B2 (en) * 2000-08-21 2004-06-15 Kosan Biosciences, Inc. Fermentation and purification of migrastatin and analog
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
MXPA03011784A (es) * 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US6989131B2 (en) * 2002-03-12 2006-01-24 Uop Llc Catalytic reactor with integral evaporator
DK1532131T3 (da) * 2002-08-29 2009-02-09 Pfizer Motilid-forbindelser
EP1641437A4 (en) * 2003-07-09 2009-06-03 Chong Kun Dang Pharm Corp SOLID DISPERSION OF TACROLIMUS
WO2005020993A1 (en) 2003-08-29 2005-03-10 Lifecycle Pharma A/S Modified release compositions comprising tacrolimus
PT1663217E (pt) * 2003-08-29 2010-10-18 Lifecycle Pharma As Dispersão sólida que compreende tacromílus
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
AU2006203946B2 (en) * 2005-01-03 2009-07-23 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
WO2007053193A2 (en) 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
EP2604269B1 (en) 2005-11-01 2014-09-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
GB0602632D0 (en) * 2006-02-08 2006-03-22 Pliva Istrazivacki Inst D O O Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
WO2007146167A1 (en) 2006-06-09 2007-12-21 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2008041553A1 (en) 2006-09-26 2008-04-10 Astellas Pharma Inc. Tacrolimus sustained-release preparation
CA2674039A1 (en) 2006-12-28 2008-07-17 Astellas Pharma Inc. Sustained release formulation for tacrolimus
JP5383513B2 (ja) * 2007-03-09 2014-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 化合物およびその標的に関連する組成物ならびに方法
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
LT2167033T (lt) 2007-05-30 2017-08-10 Veloxis Pharmaceuticals A/S Kartą per dieną vartojama geriamoji vaisto forma, apimanti takrolimą
AU2008298870C1 (en) 2007-09-14 2014-10-09 The Regents Of The University Of Michigan F1F0-ATPase inhibitors and related methods
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
BRPI0820477A2 (pt) 2007-11-06 2015-06-16 Univ Michigan Compostos de benzodiazepinona úteis no tratamento de afecções da pele
CL2008000374A1 (es) * 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
KR101003042B1 (ko) 2008-03-17 2010-12-21 종근당바이오 주식회사 고순도 타크로리무스의 정제 방법
US8222272B2 (en) 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
WO2010030891A2 (en) 2008-09-11 2010-03-18 The Regents Of The University Of Michigan Aryl guanidine f1f0-atpase inhibitors and related methods
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
WO2011035124A1 (en) 2009-09-18 2011-03-24 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
JP5856063B2 (ja) 2009-11-17 2016-02-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物
WO2011062766A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
RS55118B1 (sr) 2010-02-17 2016-12-30 Veloxis Pharmaceuticals As Stabilizovana takrolimus kompozicija
ES2549037T3 (es) 2010-06-14 2015-10-22 Ratiopharm Gmbh Composición sólida que contiene ivabradina
WO2012026896A1 (en) 2010-08-25 2012-03-01 Les Laboratoires Medis Sa Surface modified micronized tacrolimus crystalline particles and pharmaceutical compositions thereof
KR101243938B1 (ko) * 2010-10-19 2013-03-19 이희엽 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
US9757465B2 (en) 2012-04-11 2017-09-12 Dow Global Technologies Llc Composition comprising an organic diluent and a cellulose ether
CN105530918A (zh) * 2013-09-25 2016-04-27 陶氏环球技术有限责任公司 包含有机液体稀释剂和特定羟烷基甲基纤维素的组合物
CN105828827A (zh) 2014-11-21 2016-08-03 杭州领业医药科技有限公司 一种含他克莫司的药物组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130099C (cg-RX-API-DMAC7.html) * 1963-10-11
DE1492034A1 (de) * 1965-05-18 1969-02-20 Merck Ag E Verfahren zur Herstellung fester haltbarer Zubereitungen von empfindlichen,in Wasser schwer loeslichen Wirkstoffen,vorzugsweise Arzneimitteln
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
GB1322306A (en) * 1971-04-15 1973-07-04 Meiji Seika Co Stabilized antibiotic preparation and manufacturing process therefor
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
GB1593261A (en) * 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Тенцова А.И и др. Твердые дисперсные системы в фармации.-Фармаци , 1981, №2, с. 65. *

Also Published As

Publication number Publication date
KR870010073A (ko) 1987-11-30
JPH0536411B2 (cg-RX-API-DMAC7.html) 1993-05-31
DK140487A (da) 1987-10-03
UA13209A (uk) 1997-02-28
CA1302279C (en) 1992-06-02
DE3777223D1 (de) 1992-04-16
IE59712B1 (en) 1994-03-23
EP0240773B1 (en) 1992-03-11
HK6397A (en) 1997-01-24
ES2032397T3 (es) 1993-02-16
DK140487D0 (da) 1987-03-18
GR3004124T3 (cg-RX-API-DMAC7.html) 1993-03-31
GB8608080D0 (en) 1986-05-08
KR950007209B1 (ko) 1995-07-04
DK174979B1 (da) 2004-04-05
KR890001626A (ko) 1989-03-28
KR950007210B1 (ko) 1995-07-04
MX9202945A (es) 1992-07-01
EP0240773A1 (en) 1987-10-14
IE870843L (en) 1987-10-02
ATE73327T1 (de) 1992-03-15
JPS62277321A (ja) 1987-12-02
US4916138A (en) 1990-04-10

Similar Documents

Publication Publication Date Title
RU1826977C (ru) Способ получени твердой дисперсной композиции
JP2917305B2 (ja) Ｆｒ−９０１１５５物質およびその生産法
AU2014336747B2 (en) Crystal form of (r)-praziquantel and preparation method and application thereof
EP0545194A1 (en) Stable formulation of enalapril salt, a process for the preparation thereof and the use thereof
JP2001501176A (ja) 抗寄生虫薬
NZ210606A (en) Acetyl erythromycin stearate, preparation and compositions
WO1997039999A1 (en) Novel terphenyl compounds and medicines containing the same
JPWO1997039999A1 (ja) 新規テルフェニル化合物およびそれを含有する医薬
JPH029381A (ja) 抗生物質
CZ279307B6 (cs) Rebeccamycinový analog, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
RU2202556C2 (ru) Фосфорилированные производные фенилуксусной кислоты, лекарственное средство для лечения аллергических заболеваний
RU2228337C2 (ru) Ванкорезмицин (варианты), его использование, штамм amycolatopsis вида hil-006734 для его получения
SU1056901A3 (ru) Способ получени сесквитерпеновых производных или их солей
US8501764B2 (en) Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
EP0369503B1 (en) Method for the control of pneumocystis carinii
AU2002250997B2 (en) Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of CNS disorders and a process for the preparation thereof
KR920006880B1 (ko) 항생물질 x-14889 a, b, c 및 d의 제조방법
US6277860B1 (en) Furopyridine antibacterials
EP0808843B1 (en) Novel macrolide compound 0406
CZ20032426A3 (cs) Deriváty caloporosidu, léčiva s jejich obsahem, způsob přípravy těchto látek pomocí mikroorganismu a tento mikroorganismus
EP0818464A1 (en) Methylsulfomycin l, a process for its production and its use
EP0572056A1 (en) Active principle based on avermectins, related strain and process for the preparation thereof, as well as veterinary composition containing it
CZ20021404A3 (cs) Způsob přípravy aromatických diketoderivátů a jejich farmaceutické vyuľití
JP2780828B2 (ja) ポリエーテル抗生物質ｍｉ２１５―ｎｆ３物質及びその製造法、並びに鶏のコクシジウム症の防除剤
JPH0316925B2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
REG Reference to a code of a succession state

Ref country code: RU

Ref legal event code: PD4A